Erasca (NASDAQ:ERAS – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03), FiscalAI reports.
Erasca Trading Up 1.0%
Erasca stock traded up $0.19 on Tuesday, hitting $18.31. 3,426,108 shares of the stock traded hands, compared to its average volume of 6,297,791. Erasca has a 1 year low of $1.33 and a 1 year high of $24.28. The firm has a market cap of $5.69 billion, a P/E ratio of -19.69 and a beta of 0.66. The business’s fifty day simple moving average is $16.89 and its 200 day simple moving average is $14.83.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on ERAS shares. HC Wainwright reaffirmed a “buy” rating on shares of Erasca in a research report on Tuesday, July 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Erasca in a research report on Thursday, June 11th. Bank of America increased their price target on shares of Erasca from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 14th. Wolfe Research set a $16.00 price objective on shares of Erasca in a report on Thursday, June 4th. Finally, Mizuho cut their price objective on Erasca from $28.00 to $26.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 12th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $21.64.
Key Stories Impacting Erasca
Here are the key news stories impacting Erasca this week:
- Positive Sentiment: Erasca reported updated U.S. trial data showing compelling monotherapy efficacy and continued favorable tolerability for ERAS-0015 in second-line or later KRAS G12X pancreatic cancer. The company also highlighted further progress in an ERAS-0015/panitumumab combination study for colorectal cancer, supporting the drug’s development prospects. Erasca Reports Second Quarter 2026 Business Updates and Financial Results
- Positive Sentiment: The appointment of internationally recognized oncologist Charles S. Fuchs as president of research and development may strengthen Erasca’s clinical and regulatory leadership as its oncology pipeline advances. Erasca Strengthens R&D Leadership
- Neutral Sentiment: A reported short-interest figure of zero shares implies no measurable short position, but the data appears anomalous and is unlikely to provide a meaningful trading signal. Erasca Short Interest Information
- Negative Sentiment: Erasca reported a quarterly loss of $0.14 per share, worse than the $0.11 consensus loss. The earnings miss reinforces near-term concerns about cash consumption and continued losses while the company funds clinical development. Erasca Quarterly Earnings Release
- Negative Sentiment: Several law firms announced or promoted a securities class action alleging that Erasca and senior executives misled investors about ERAS-0015’s competitive advantages, safety profile, and intellectual-property protection. The allegations have not been proven, but the litigation creates reputational, legal-cost, and potential financial risks for shareholders. Erasca Securities Class Action Notice
- Negative Sentiment: The company’s inducement grants may modestly increase potential share dilution, although the grants are intended to help attract and retain employees. Erasca Inducement Grants
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of ERAS. VR Adviser LLC boosted its stake in Erasca by 10.1% during the second quarter. VR Adviser LLC now owns 17,857,083 shares of the company’s stock worth $22,678,000 after acquiring an additional 1,640,867 shares in the last quarter. Paradigm Biocapital Advisors LP lifted its stake in shares of Erasca by 4.4% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 14,159,095 shares of the company’s stock worth $52,672,000 after buying an additional 599,078 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Erasca by 0.9% during the third quarter. Vanguard Group Inc. now owns 12,811,832 shares of the company’s stock valued at $27,930,000 after buying an additional 116,235 shares during the last quarter. Vivo Capital LLC increased its position in shares of Erasca by 37.2% during the third quarter. Vivo Capital LLC now owns 9,273,428 shares of the company’s stock valued at $20,216,000 after acquiring an additional 2,516,672 shares in the last quarter. Finally, State Street Corp lifted its position in Erasca by 53.2% in the 4th quarter. State Street Corp now owns 6,174,642 shares of the company’s stock valued at $22,970,000 after acquiring an additional 2,145,386 shares in the last quarter. 67.78% of the stock is currently owned by institutional investors.
About Erasca
Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.
Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.
Featured Stories
- Five stocks we like better than Erasca
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Erasca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erasca and related companies with MarketBeat.com's FREE daily email newsletter.
